Sub-component for Institution # 16-01848 Core 1 - Administrative

机构的子组件

基本信息

项目摘要

CORE 1 Summary The primary objective of the Administrative Core, Core 1, is to provide overall administrative support to the program. This administrative support will include communication with the institutional administration, maintaining and distributing records regarding the fiscal management of the grant, preparing annual program reports, and coordinating the meetings of the advisory committees and interfacing with investigators at other institutions involved. In addition, the Administrative Core will maintain records of such things as Institutional Animal Care and Use Committee approvals, and other institutional compliance items. These activities will be under the direction of Dr. Waldemar Debinski and he will be supported by Dr. King Li and advised by the project and core investigators concerning all aspects of progress on the project and administrative issues. The administrative team is made up of senior investigators serving as project and core leaders or co-investigators and an administrative secretary and program manager with extensive experience in coordinating and managing the activities of larger groups. The following specific aims and objectives are proposed: 1) To promote efficient use of the PPG's resources, including adherence of cores to standards to ensure high quality data output and prioritizing access; 2) to promote the exchange of scientific ideas and data within not only the PO1 Working Group, made up of the Project Leaders, the Directors of the Cores, and the Co-investigators participating in this PPG, but also with the investigators who are part of the program and located at other institutions, and with the larger scientific community; 3) to provide internal and external review of the progress made by the PPG.
核心1 概括 行政核心核心1的主要目标是为 程序。这种行政支持将包括与机构管理的沟通, 维护和分发有关赠款财政管理的记录,准备年度计划 报告,并协调咨询委员会的会议,并与其他调查人员接触 涉及的机构。此外,行政核心将保留诸如机构之类的事物的记录 动物护理和使用委员会批准以及其他机构合规项目。这些活动将是 在Waldemar Debinski博士的指导下,他将得到李国王的支持,并由 项目和核心调查人员涉及项目和行政问题进展的各个方面。这 行政团队由作为项目和核心领导者或共同研究人员的高级调查员组成 以及具有丰富协调和协调经验的行政秘书和计划经理 管理较大群体的活动。 提出了以下具体目的和目标:1)有效利用PPG资源, 包括核心遵守标准,以确保高质量的数据输出并确定访问的优先级; 2)到 不仅在PO1工作组中促进科学思想和数据的交流,还由 项目负责人,核心的董事以及参与该PPG的共同投资者,但也与 属于该计划并位于其他机构的调查人员,并且具有更大的科学 社区; 3)对PPG取得的进度进行内部和外部审查。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Waldemar Debinski其他文献

Waldemar Debinski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Waldemar Debinski', 18)}}的其他基金

Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
使用多价药物偶联物进行 GBM 治疗的组合免疫疗法
  • 批准号:
    10560392
  • 财政年份:
    2022
  • 资助金额:
    $ 12.55万
  • 项目类别:
Multi-receptor Targeting of Glioblastoma
胶质母细胞瘤的多受体靶向
  • 批准号:
    10693378
  • 财政年份:
    2021
  • 资助金额:
    $ 12.55万
  • 项目类别:
Multi-receptor Targeting of Glioblastoma
胶质母细胞瘤的多受体靶向
  • 批准号:
    10313101
  • 财政年份:
    2021
  • 资助金额:
    $ 12.55万
  • 项目类别:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
机构的子组件
  • 批准号:
    10220881
  • 财政年份:
    2017
  • 资助金额:
    $ 12.55万
  • 项目类别:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
机构的子组件
  • 批准号:
    10493966
  • 财政年份:
    2017
  • 资助金额:
    $ 12.55万
  • 项目类别:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
最大限度地提高胶质母细胞瘤的本地治疗交付机会
  • 批准号:
    9978729
  • 财政年份:
    2017
  • 资助金额:
    $ 12.55万
  • 项目类别:
Rapid Electrical Impedance Spectroscopy for Detection of High-Frequency Irreversible Electroporation Ablation Growth in a Rodent Glioma Model
快速电阻抗光谱法检测啮齿动物神经胶质瘤模型中高频不可逆电穿孔消融生长
  • 批准号:
    10310562
  • 财政年份:
    2017
  • 资助金额:
    $ 12.55万
  • 项目类别:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
最大限度地提高胶质母细胞瘤的本地治疗交付机会
  • 批准号:
    10220880
  • 财政年份:
    2017
  • 资助金额:
    $ 12.55万
  • 项目类别:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
多形性胶质母细胞瘤的分子组合治疗
  • 批准号:
    8010645
  • 财政年份:
    2010
  • 资助金额:
    $ 12.55万
  • 项目类别:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
多形性胶质母细胞瘤的分子组合治疗
  • 批准号:
    8385587
  • 财政年份:
    2010
  • 资助金额:
    $ 12.55万
  • 项目类别:

相似海外基金

Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
  • 批准号:
    10643145
  • 财政年份:
    2023
  • 资助金额:
    $ 12.55万
  • 项目类别:
I-TrainED: Innovative Training and Education in Diabetes
I-TrainED:糖尿病创新培训和教育
  • 批准号:
    10795135
  • 财政年份:
    2023
  • 资助金额:
    $ 12.55万
  • 项目类别:
Atlanta Network for Training In KUH Scientific Research (ATLANTIS)
亚特兰大 KUH 科学研究培训网络 (ATLANTIS)
  • 批准号:
    10705256
  • 财政年份:
    2022
  • 资助金额:
    $ 12.55万
  • 项目类别:
UNC CASCADE Network Research Base
UNC CASCADE网络研究基地
  • 批准号:
    10696082
  • 财政年份:
    2022
  • 资助金额:
    $ 12.55万
  • 项目类别:
Midcareer Development Award in Neuroaging and Geriatric Pharmacoepidemiology Research
神经衰老和老年药物流行病学研究职业中期发展奖
  • 批准号:
    10351611
  • 财政年份:
    2022
  • 资助金额:
    $ 12.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了